Qube Research & Technologies LTD Biocryst Pharmaceuticals Inc Transaction History

Qube Research & Technologies LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$4.89 - $7.65 $1.77 Million - $2.76 Million	-361,109 Reduced 35.11%	667,394 $3.39 Million
Q4 2023 Feb 13, 2024	BUY	$4.98 - $6.77 $5.12 Million - $6.96 Million	1,028,503 New	1,028,503 $6.16 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $1.49 Million - $1.89 Million	214,095 New	214,095 $1.51 Million
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $575,547 - $714,877	-40,503 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$9.5 - $17.24 $54,615 - $99,112	-5,749 Reduced 12.43%	40,503 $640,000
Q1 2021 May 14, 2021	BUY	$7.37 - $13.61 $340,877 - $629,489	46,252 New	46,252 $470,000
Q3 2020 Nov 12, 2020	SELL	$3.43 - $5.53 $757,656 - $1.22 Million	-220,891 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $419,692 - $1.24 Million	220,891 New	220,891 $1.05 Million
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $23,737 - $60,975	-14,836 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$1.59 - $3.45 $23,589 - $51,184	14,836 New	14,836 $51,000

257

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.57B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.